Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ly5.5
L-Lysine – Forschung
Hilft wahrscheinlich
57 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
L-Lysine scheint in 6 von 8 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1969–2026 mit einer typischen Studiengröße von 55 Teilnehmenden.
Basierend auf 57 Studien · 3 Meta-Analysen · 48 RCTs · 3,245 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
6geholfen2unklar· 49 weitere ohne bewertete Effektdaten
Nach Outcome
Glucose & metabolic
Hilft wahrscheinlich18 Studien
Cold sores & HSV
Überwiegend Mechanismus / Beobachtung8 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung7 Studien
Digestive health
Gemischte Evidenz5 Studien
Anxiety & stressReduces cortisol and anxiety in lysine-deficient populations · 2-4 weeks
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
Bone healthSupports bone mineral density and skeletal strength · 8-12 weeks
Zu wenige bewertete Studien2 Studien
Skin health
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Vision & eye health
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 15 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
71%
über Studien hinweg
Untersuchte Personen
3,245
typische Studie: 55 Personen
Stärkste Designs
51
3 gepoolt, 48 randomisiert
Zeigte Nutzen
75%
6/8 Studien
Wie lange Studien liefen
Unter einer Woche
2
1–4 Wochen
1
1–3 Monate
1
3+ Monate
3
Untersuchte Populationen
General population2
Schizophrenia patients1
Healthy participants and T2DM/obese individuals1
Healthy human subjects1
Stetige Forschung
10 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
196919972026
1Total symptomatology in schizophreniaMeta-Analysen=50 · small study2025
Fornaro M et al. · Molecular psychiatry (2025)
Groß Nutzen
← SchlechterKein EffektBesser →
Change (Standardized Mean Difference = SMD) in total symptomatology and acceptability (Risk Ratio = RR) were co-primary outcomes.
High heterogeneity (tau2 = 0.10, I2 = 55.9%) and global inconsistency (Q = 40.79, df = 18, p = 0.002) emerged without publication bias (Egger's test, p = 0.42).
2Postprandial glucose and insulin response to amino acidsSystematische Übersichtn=55 · small study2020
Einfach gesagt: The extracted information is publicly available and can serve multiple purposes such as computational modeling.
Sloun BV et al. · Nutrients (2020)
Oral ingestion of most individual AAs induced an insulin response, but did not alter glucose concentrations in healthy participants.
Specific AAs (i.e., leucine and isoleucine) co-ingested with glucose exerted a synergistic effect on the postprandial insulin response and attenuated the glucose response compared to glucose intake alone in healthy participants.
Oral AA ingestion as well as intravenous AA infusion was able to stimulate an insulin response and decrease glucose concentrations in T2DM and obese individuals.
3Risk of gastrointestinal symptomsSystematische Übersichtn=71 · small study2019
Einfach gesagt: Integrated analysis of the risk for developing gastrointestinal symptoms revealed that the risk ratio was 1.02 (95% CI, 0.96-1.07; p = 0.49); thus, no significant increase was observed. (UMIN000028914).
Hayamizu K et al. · Amino acids (2019)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Could be chance
Integrated analysis of the risk for developing gastrointestinal symptoms revealed that the risk ratio was 1.02 (95% CI, 0.96-1.07; p = 0.49); thus, no significant increase was observed. (UMIN000028914).
The dose range of L-lysine in the selected studies was 16.8-17,500 mg/day, and the range of dosing period was 1-1095 days.
The observed adverse events were mainly subjective symptoms related to the gastrointestinal tract such as nausea, stomachache, and diarrhea.
4Systematische Übersichtn=2,619 · very large study2010
Einfach gesagt: Based on the available evidence, it appears that nutritional and herbal supplementation is an effective method for treating anxiety and anxiety-related conditions without the risk of serious side effects.
Lakhan SE et al. · Nutrition journal (2010)
Of the randomized controlled trials reviewed, 71% (15 out of 21) showed a positive direction of evidence.
Based on the available evidence, it appears that nutritional and herbal supplementation is an effective method for treating anxiety and anxiety-related conditions without the risk of serious side effects.
There is the possibility that any positive effects seen could be due to a placebo effect, which may have a significant psychological impact on participants with mental disorders.
5Safety of l-Lysine supplementationSystematische Übersicht2020
Einfach gesagt: The provisional no-observed-adverse-effect level in healthy human subjects was based on gastrointestinal symptoms and identified at 6.0 g/d.
Hayamizu K et al. · The Journal of nutrition (2020)
Kein klarer Effekt
← SchlechterKein EffektBesser →
The observed adverse events were mainly subjective gastrointestinal tract symptoms; however, the risk analysis for incidence of gastrointestinal symptoms was not statistically significant (risk ratio of 1.02).
The provisional no-observed-adverse-effect level in healthy human subjects was based on gastrointestinal symptoms and identified at 6.0 g/d.
Einfach gesagt: L-lysine supplementation appears to be ineffective for prophylaxis or treatment of herpes simplex lesions with doses of less than 1 g/d without low-arginine diets. Doses in excess of 3 g/d appear to improve patients' subjective experience of the disease.
Mailoo VJ et al. · Integrative Medicine (2017)
L-lysine supplementation appears to be ineffective for prophylaxis or treatment of herpes simplex lesions with doses of less than 1 g/d without low-arginine diets.
Doses in excess of 3 g/d appear to improve patients' subjective experience of the disease.
Longer duration controlled studies of daily lysine doses exceeding 1.2 g/d are required to definitively test its role in herpes simplex prophylaxis.
7Lumbar disc volume changesRCT2024
Einfach gesagt: In conclusion, this multi-nutrient supplement might not only stabilize the progression of lumbar osteochondrosis, but it might also potentially even increase IVD volumes as detected on MRIs.
Laky B et al. · Nutrients (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Despite no significance regarding the distribution of Pfirrmann grade changes (improvement, no change, worsening; p = 0.259), in the supplement group, one patient achieved a three-grade improvement, and worsening of Pfirrmann grades were only detected in the placebo group (9.1%).
Disc degeneration according to Pfirrmann classifications remained stable during the 3-month intervention in both groups.
Furthermore, in-depth evaluations of MRIs showed significantly higher 3D-measured volume changes (increase) in the supplement (+740.3 ± 796.1 mm3) compared to lower 3D-measured volume changes (decrease) in the placebo group (-417.2 ± 875.0 mm3; p < 0.001).
19Postprandial glucose iAUC0-120minRCTn=60 · small study2020
Einfach gesagt: Future studies should clarify, whether regular consumption of the supplement improves markers of disease or could play a role in a diet aiming at preventing the development of diabetes.
Östman E et al. · PloS one (2020)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
In the intention-to-treat-analysis (n = 60) the supplement resulted in a decreased venous blood glucose iAUC0-120min compared to placebo, mean (SE) of 68.7 (6.6) versus 52.2 (6.8) respectively, a difference of -16.5 mmol/L•min (95% CI -3.1 to -30.0, p = 0.017).
The Cmax for venous blood glucose for the supplement and placebo were 6.45 (0.12) versus 6.10 (<0.12), respectively, a difference of -0.35 mmol/L (95% CI -0.17 to -0.53, p<0.001).
In the per protocol-analysis (n = 48), the supplement resulted in a decreased Cmax compared to placebo from 6.42 (0.14) to 6.12 (0.14), a difference of -0.29 mmol/L (95% CI -0.12 to -0.47, p = 0.002).